“JAK1 or JAK1/2 Inhibitors Rapidly Reduce Refractory Pruritus in Dystrophic Epidermolysis Bullosa: A Case Series”

https://pubmed.ncbi.nlm.nih.gov/38115742

The abstract reports a case series where oral JAK1 or JAK1/2 inhibitors (upadacitinib or baricitinib) showed rapid and sustained reduction in refractory pruritus in patients with dystrophic epidermolysis bullosa, without serious adverse events.